Qsam Biosciences Stock EBITDA
Qsam Biosciences fundamentals help investors to digest information that contributes to Qsam Biosciences' financial success or failures. It also enables traders to predict the movement of Qsam OTC Stock. The fundamental analysis module provides a way to measure Qsam Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Qsam Biosciences otc stock.
Qsam |
Qsam Biosciences OTC Stock EBITDA Analysis
Qsam Biosciences' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Qsam Biosciences EBITDA | (3.94 M) |
Most of Qsam Biosciences' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Qsam Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
CompetitionAccording to the company disclosure, Qsam Biosciences reported earnings before interest,tax, depreciation and amortization of (3.94 Million). This is 100.45% lower than that of the Biotechnology sector and 103.94% lower than that of the Health Care industry. The ebitda for all United States stocks is 100.1% higher than that of the company.
Qsam EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Qsam Biosciences' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Qsam Biosciences could also be used in its relative valuation, which is a method of valuing Qsam Biosciences by comparing valuation metrics of similar companies.Qsam Biosciences is currently under evaluation in ebitda category among its peers.
Qsam Fundamentals
| Return On Equity | -33.77 | |||
| Return On Asset | -2.38 | |||
| Current Valuation | 36.03 M | |||
| Shares Outstanding | 4.45 M | |||
| Shares Owned By Insiders | 52.36 % | |||
| Price To Book | 201.64 X | |||
| Price To Sales | 1.71 X | |||
| Gross Profit | 916.67 K | |||
| EBITDA | (3.94 M) | |||
| Net Income | (4.39 M) | |||
| Cash And Equivalents | 429.35 K | |||
| Cash Per Share | 0.25 X | |||
| Total Debt | 7.5 K | |||
| Debt To Equity | 2.08 % | |||
| Current Ratio | 0.23 X | |||
| Book Value Per Share | 0.04 X | |||
| Cash Flow From Operations | (2.85 M) | |||
| Earnings Per Share | (1.69) X | |||
| Beta | 1.81 | |||
| Market Capitalization | 73.79 B | |||
| Total Asset | 1.71 M | |||
| Retained Earnings | (40.16 M) | |||
| Working Capital | 672.35 K | |||
| Net Asset | 1.71 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in nation. Note that the Qsam Biosciences information on this page should be used as a complementary analysis to other Qsam Biosciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Other Consideration for investing in Qsam OTC Stock
If you are still planning to invest in Qsam Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Qsam Biosciences' history and understand the potential risks before investing.
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Stocks Directory Find actively traded stocks across global markets | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data |